Document is current
Any future updates will be listed below
-
Authors
Maffezzoli, Michele
Signori, Alessio
Acunzo, Alessandro
Buti, Sebastiano
Bosoni, Michela
Verzoni, Elena
Di Marco, Andrea
Lolli, Cristian
Di Napoli, Marilena
Fanelli, Martina
Volta, Alberto Dalla
Masini, Cristina
Roviello, Giandomenico
Iacovelli, Roberto
Mennitto, Alessia
Filippi, Roberto
Sorarù, Mariella
Formisano, Luigi
Guida, Annalisa
Fantinel, Emanuela
Messina, Carlo
Bonomi, Lucia
Scagliarini, Sarah
Nasso, Cecilia
Chiellino, Silvia
Maiorano, Brigida Anna
Deppieri, Filippo
Cavo, Alessia
Conteduca, Vincenza
Zai, Silvia
Zucali, Paolo Andrea
Tucci, Marcello
Vignani, Francesca
La Russa, Francesca
Lombardo, Laura
Caserta, Claudia
Paolieri, Federico
Bertolotti, Francesca
Rescigno, Pasquale
Banna, Giuseppe Luigi
Fornarini, Giuseppe
Bimbatti, Davide
Rebuzzi, Sara Elena
-
Funding
Funding for this research was provided by:
Università degli Studi di Parma
- License Information
-
More Information
Article History
Received: 24 October 2025
Accepted: 22 January 2026
First Online: 3 February 2026
Declarations
:
: SE Rebuzzi received honoraria as a speaker at scientific events and travel accommodations from Astellas, Janssen, Ipsen, MSD, GSK, and Bristol-Myers Squibb. G Fornarini services advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD, and Merck, and received travel accommodations from Astellas, Janssen, and Bay er. S Buti received honoraria as a speaker at scientific events and in an advisory role by BMS, Pfizer, MSD, Ipsen, Roche, Eli Lilly, AstraZeneca, Pierre-Fabre, Novartis, Mer ck, Gentili, and Astellas. GL Banna reports personal fees from AstraZeneca and Astellas for speakers bureaus. P Rescigno services advisory boards for MSD, AstraZeneca, and Janssen. C Masini received personal fees as a speaker from Astellas; as a consultant from Ipsen, MSD, and Janssen; and for travel accommodations from Bristol-Myers Squibb, Pfizer, Astellas, Janssen, and Ipsen. The other authors declare they have no conflicts of interest to disclose.
: The authors state that they have obtained appropriate institutional review board approval. The study protocol was approved by the Ethics Committee of Istituto Oncologico Veneto IOV IRCCS of Padua on 1st June 2023 (Registration number: CESC IOV 2023-78). Documented approval from the Local Ethics Committee of each participating centre was required before study activation at each site. The Authors have follow ed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations in volving human subjects, informed consent has been obtained from all the participants involved.
